Skip to main content

Development of Robust and Innovative Vaccine Effectiveness

Objective

Influenza is a major public health problem. In a conservative estimate, influenza infects annually 60 of the 500 million inhabitants of the EU. Vaccines are the cornerstone for preventing influenza and its consequences. Current influenza vaccines have a moderate variable effect, given the mismatch between vaccine and circulating strains, waning immunity and interference from previous vaccination, among others.

The single most important challenge in achieving VE studies for the various influenza vaccines put every year on the European market is the ability of the different stakeholders to work in collaboration.

To enable a sustainable network of influenza vaccine VE studies, the Development of Robust and Innovative Vaccines Effectiveness (DRIVE) main goal will be the development of a governance model between public and private entities. This model will ensure scientific independence in the studies and full transparency, allowing different stakeholders to fulfill their needs taking into account their respective obligations and statutes.

A second challenge will be to reach the capacity to perform vaccine brand- specific effectiveness studies, which is agile enough to deliver the needed outputs in timely manner, and robust enough to provide results by different age and risk groups and flexible enough to utilize novel tools while at the same time aims to be sustainable.

Combining these outputs, DRIVE will establish a sustainable platform for joint influenza vaccine effectiveness evaluation which will have a positive impact on European citizens public health.

Field of science

  • /medical and health sciences/health sciences/public and environmental health
  • /medical and health sciences/health sciences/infectious disease/RNA virus/influenza
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug/vaccines
  • /social sciences/sociology/governance

Call for proposal

H2020-JTI-IMI2-2016-09-two-stage
See other projects for this call

Funding Scheme

IMI2-RIA - Research and Innovation action

Coordinator

FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA
Address
Calle Micer Masco 31
46010 Valencia
Spain
Activity type
Research Organisations
EU contribution
€ 5 339 883,75

Participants (16)

INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT

Participation ended

France
EU contribution
€ 89 590,50
Address
Boulevard De Dunkerque 44 Cs 90009
13572 Marseille
Activity type
Research Organisations
P95 CVBA
Belgium
EU contribution
€ 502 437,50
Address
Koning Leopold Iii - Laan 1
3001 Leuven
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSITA DEGLI STUDI DI FIRENZE
Italy
EU contribution
€ 350 812,50
Address
Piazza San Marco 4
50121 Florence
Activity type
Higher or Secondary Education Establishments
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL
Spain
EU contribution
€ 393 750
Address
Calle Velazquez 94 Planta 1
28006 Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
TERVEYDEN JA HYVINVOINNIN LAITOS
Finland
EU contribution
€ 349 250
Address
Mannerheimintie 166
00271 Helsinki
Activity type
Research Organisations
ISTITUTO SUPERIORE DI SANITA
Italy
EU contribution
€ 211 047,69
Address
Viale Regina Elena 299
00161 Roma
Activity type
Research Organisations
UNIVERSITY OF SURREY
United Kingdom
EU contribution
€ 407 303,75
Address
Stag Hill
GU2 7XH Guildford
Activity type
Higher or Secondary Education Establishments
CONFEDERATION OF MENINGITIS ORGANISATIONS LTD
United Kingdom
EU contribution
€ 161 500
Address
Newminster House Baldwin Street
BS1 1LT Bristol
Activity type
Other
UNIVERSITE LYON 1 CLAUDE BERNARD
France
EU contribution
€ 315 250
Address
Boulevard Du 11 Novembre 1918 Num43
69622 Villeurbanne Cedex
Activity type
Higher or Secondary Education Establishments
ASSOCIATION INTERNATIONALE DE STANDARDISATION BIOLOGIQUE POUR L'EUROPE(IABS-EU)
France
EU contribution
€ 343 437,50
Address
Boulevartd Vivier Merle 10-12 World Trade Center Tour Oxygene
69393 Lyon
Activity type
Other
SANOFI PASTEUR SA
France
EU contribution
€ 0
Address
Avenue Pont Pasteur, 2
69007 Lyon
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ABBOTT BIOLOGICALS BV
Netherlands
EU contribution
€ 0
Address
C.j. Van Houtenlaan 36
1381 CP Weesp
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SEQIRUS UK LIMITED
United Kingdom
EU contribution
€ 0
Address
Point 29 Market Street
SL6 8AA Maidenhead
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
GLAXOSMITHKLINE BIOLOGICALS SA
Belgium
EU contribution
€ 0
Address
Rue De L Institut 89
1330 Rixensart
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
OSPEDALE PEDIATRICO BAMBINO GESU
Italy
EU contribution
€ 321 452,31
Address
Piazza Sant Onofrio 4
00165 Roma
Activity type
Other
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
France
EU contribution
€ 214 097
Address
Rue De Tolbiac 101
75654 Paris
Activity type
Research Organisations